Acrivon Therapeutics (ACRV) CMO granted stock options on 174,068 shares

Rhea-AI Filing Summary

Acrivon Therapeutics Chief Medical Officer Mirza Mansoor Raza received a grant of stock options covering 174,068 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase. According to the vesting schedule, 25% of the shares vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, subject to his continuous service through each vesting date. Following this award, he holds options on 174,068 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mirza Mansoor Raza

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	174,068	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 174,068 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mirza Mansoor Raza

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.51	03/01/2026		A		174,068		(1)	02/29/2036	Common Stock	174,068	$0	174,068	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Mirza Mansoor Raza?

Acrivon Therapeutics reported that Chief Medical Officer Mirza Mansoor Raza received a grant of stock options for 174,068 shares at an exercise price of $0.00 per share. This reflects an equity compensation award rather than an open-market stock purchase or sale.

How many Acrivon Therapeutics (ACRV) shares are covered by the new stock option grant?

The new stock option award to Acrivon Therapeutics Chief Medical Officer Mirza Mansoor Raza covers 174,068 shares of common stock. These options represent potential future share ownership, subject to the vesting schedule and his continued service with the company over time.

What is the vesting schedule for Mirza Mansoor Raza’s ACRV stock options?

For Mirza Mansoor Raza’s ACRV option grant, 25% of the 174,068 shares vest on March 1, 2027. The remaining shares then vest in 36 substantially equal monthly installments, conditioned on his continuous service with Acrivon Therapeutics through each vesting date.

Is the ACRV stock option grant to Mirza Mansoor Raza an open-market purchase?

No, the ACRV transaction is a compensatory stock option grant with an exercise price of $0.00 per share. It is classified as a grant or award acquisition, not an open-market buy, and is intended as equity-based compensation for the Chief Medical Officer.

How many ACRV derivative securities does Mirza Mansoor Raza hold after this transaction?

After this transaction, Mirza Mansoor Raza holds stock options covering 174,068 ACRV shares directly. This total reflects the newly granted options reported, which will vest over time according to the specified schedule tied to his continued service.